Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Diluted Average) (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $98.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) fell 3.74% to $98.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.6 million through Dec 2025, down 3.74% year-over-year, with the annual reading at $98.6 million for FY2025, 3.74% down from the prior year.
  • Shares Outstanding (Diluted Average) hit $98.6 million in Q4 2025 for ARS Pharmaceuticals, roughly flat from $98.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $102.4 million in Q4 2024 to a low of $28.9 million in Q4 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $75.7 million across 5 years, with a median of $95.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 11.84% in 2022 and later skyrocketed 210.77% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $28.9 million in 2021, then skyrocketed by 38.39% to $40.0 million in 2022, then soared by 138.3% to $95.2 million in 2023, then increased by 7.54% to $102.4 million in 2024, then fell by 3.74% to $98.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SPRY at $98.6 million in Q4 2025, $98.8 million in Q3 2025, and $98.2 million in Q2 2025.